Active Ingredient(s):Pexidartinib Hydrochloride FDA Approved: * August 2, 2019 Pharm Company: *DAIICHI SANKYO INC
Pexidartinib, sold under the brand name Turalio, is a kinase inhibitor drug for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Pexidartinib blocks the activity of the colony-stimulating factor-1 receptor (CSF-1R). 
Common side effects are increased lactate dehydrogenase (proteins tha...
* May have multiple approval dates, manufacturers, or labelers.